Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. It offers leukemia-related fusion gene, human estimated glomerular filtration rate gene mutation, genotype, human rubella virus, small ureaplasma, herpes simplex virus type 12 nucleic acid, and hepatitis B virus gene mutation detection kits. The company was founded by Hui Xiong on February 17, 2012 and is headquartered in Shanghai, China.